Literature DB >> 25236570

An Oct-1-based, feed-forward mechanism of apoptosis inhibited by co-culture with Raji B-cells: towards a model of the cancer cell/B-cell microenvironment.

Karoly Szekeres1, Rudra Koul1, James Mauro1, Mark Lloyd2, Joseph Johnson2, George Blanck3.   

Abstract

A continuing conundrum of cancer biology is the dichotomous function of transcription factors that regulate both proliferation and apoptosis, seemingly opposite results. Previous results have indicated that regulated entry into the S-phase of the cell cycle can be anti-apoptotic. Indeed, tumor suppressor genes can be amplified in tumors and certain, slow growing cancers can represent a relatively poor prognosis, both phenomena likely related to reduced cancer cell apoptosis, in turn due to reduced, unproductive entry into S-phase. In this report, we demonstrate that the Oct-1 transcription factor, commonly considered pro-proliferative, indeed facilitates IFN-γ induced apoptosis in 5637 bladder carcinoma cells, consistent with the role of the retinoblastoma protein in down-regulating Oct-1 DNA binding activity and in suppressing IFN-γ induced apoptosis. More importantly, despite the commonly appreciated process of IFN-γ induced apoptosis, IFN-γ at low concentrations stimulated bladder cancer cell proliferation, consistent with apoptosis being dependent on an overstimulation of what is otherwise a pro-proliferative pathway. This observation is in turn consistent with a feed forward mechanism of apoptosis, whereby transcription factors activate proliferation-effector genes at relatively low levels, then apoptosis-effector genes when the transcription factors over-accumulate. Finally, Oct-1 mediated apoptosis is inhibited by co-culture with Raji B-cells, raising the question of whether the normal lymph node environment, or other microenvironments with high concentrations of B-cells, is protective against Oct-1 facilitated apoptosis?
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B-cell microenvironment; Bladder carcinoma; Feed-forward apoptosis; Interferon-gamma; Oct-1; Transcription factors

Mesh:

Substances:

Year:  2014        PMID: 25236570      PMCID: PMC4742287          DOI: 10.1016/j.yexmp.2014.09.010

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  19 in total

1.  Oct-1 maintains an intermediate, stable state of HLA-DRA promoter repression in Rb-defective cells: an Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter.

Authors:  Aaron R Osborne; Hongquan Zhang; Gyorgy Fejer; Kimberly M Palubin; Melissa I Niesen; George Blanck
Journal:  J Biol Chem       Date:  2004-04-22       Impact factor: 5.157

Review 2.  Modulation of T cell function by TCR/pMHC binding kinetics.

Authors:  Leandro J Carreño; Pablo A González; Alexis M Kalergis
Journal:  Immunobiology       Date:  2006-01-04       Impact factor: 3.144

3.  E2F-1 functions in mice to promote apoptosis and suppress proliferation.

Authors:  S J Field; F Y Tsai; F Kuo; A M Zubiaga; W G Kaelin; D M Livingston; S H Orkin; M E Greenberg
Journal:  Cell       Date:  1996-05-17       Impact factor: 41.582

4.  Tumor induction and tissue atrophy in mice lacking E2F-1.

Authors:  L Yamasaki; T Jacks; R Bronson; E Goillot; E Harlow; N J Dyson
Journal:  Cell       Date:  1996-05-17       Impact factor: 41.582

5.  Differential DNA binding activities of the transcription factors AP-1 and Oct-1 during light-induced apoptosis of photoreceptors.

Authors:  F Hafezi; A Marti; C Grimm; A Wenzel; C E Remé
Journal:  Vision Res       Date:  1999-07       Impact factor: 1.886

6.  Retinoblastoma protein inhibits IFN-gamma induced apoptosis.

Authors:  D E Berry; Y Lu; B Schmidt; P G Fallon; C O'Connell; S X Hu; H J Xu; G Blanck
Journal:  Oncogene       Date:  1996-04-18       Impact factor: 9.867

7.  A direct mechanistic link between growth control and a tumor cell immune function: increased interleukin-8 secretion accounts for elimination of Oct-1 antisense transformants from scid mice.

Authors:  Kimberly M Palubin; Bonnie L Goodwin; Melissa I Niesen; Elizabeth A Le; Aaron R Osborne; George Blanck
Journal:  Anticancer Res       Date:  2006 May-Jun       Impact factor: 2.480

8.  Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation.

Authors:  A Osborne; H Zhang; W M Yang; E Seto; G Blanck
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

9.  Transcription factors DNA-binding activity in rat thymocytes undergoing apoptosis after heat-shock or dexamethasone treatment.

Authors:  E Sikora; E Grassilli; E Radziszewska; E Bellesia; D Barbieri; C Franceschi
Journal:  Biochem Biophys Res Commun       Date:  1993-12-15       Impact factor: 3.575

10.  Protein kinase A and AP-1 (c-Fos/JunD) are induced during apoptosis of mouse mammary epithelial cells.

Authors:  A Marti; B Jehn; E Costello; N Keon; G Ke; F Martin; R Jaggi
Journal:  Oncogene       Date:  1994-04       Impact factor: 9.867

View more
  14 in total

1.  Identification of immunoglobulin V(D)J recombinations in solid tumor specimen exome files: Evidence for high level B-cell infiltrates in breast cancer.

Authors:  Wei Lue Tong; Yaping N Tu; Mohammad D Samy; Wade J Sexton; George Blanck
Journal:  Hum Vaccin Immunother       Date:  2017-01-13       Impact factor: 3.452

2.  Recovery of Immunoglobulin VJ Recombinations from Pancreatic Cancer Exome Files Strongly Correlates with Reduced Survival.

Authors:  Jacob C Kinskey; Yaping N Tu; Wei Lue Tong; John M Yavorski; George Blanck
Journal:  Cancer Microenviron       Date:  2018-02-05

3.  Tumor suppressor genes are larger than apoptosis-effector genes and have more regions of active chromatin: Connection to a stochastic paradigm for sequential gene expression programs.

Authors:  Marlene Garcia; James A Mauro; Michael Ramsamooj; George Blanck
Journal:  Cell Cycle       Date:  2015-05-06       Impact factor: 4.534

4.  Elucidating feed-forward apoptosis signatures in breast cancer datasets: Higher FOS expression associated with a better outcome.

Authors:  Diana A Fisler; Dhiraj Sikaria; John M Yavorski; Yaping N Tu; George Blanck
Journal:  Oncol Lett       Date:  2018-06-12       Impact factor: 2.967

5.  TCGA: Increased oncoprotein coding region mutations correlate with a greater expression of apoptosis-effector genes and a positive outcome for stomach adenocarcinoma.

Authors:  John M Yavorski; George Blanck
Journal:  Cell Cycle       Date:  2016-06-29       Impact factor: 4.534

6.  Recovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade.

Authors:  Boris I Chobrutskiy; Saif Zaman; Wei Lue Tong; Andrea Diviney; George Blanck
Journal:  J Neurooncol       Date:  2018-10-31       Impact factor: 4.130

7.  Impact of SNPs on CpG Islands in the MYC and HRAS oncogenes and in a wide variety of tumor suppressor genes: A multi-cancer approach.

Authors:  Mohammad D Samy; John M Yavorski; James A Mauro; George Blanck
Journal:  Cell Cycle       Date:  2016-06-17       Impact factor: 4.534

8.  Systemic Adaptive Immune Parameters Associated with Neuroblastoma Outcomes: the Significance of Gamma-Delta T Cells.

Authors:  Etienne C Gozlan; Boris I Chobrutskiy; Saif Zaman; Michelle Yeagley; George Blanck
Journal:  J Mol Neurosci       Date:  2021-03-05       Impact factor: 3.444

9.  Elevated OCT1 participates in colon tumorigenesis and independently predicts poor prognoses of colorectal cancer patients.

Authors:  Yu-Peng Wang; Guo-He Song; Jian Chen; Chao Xiao; Chao Li; Lin Zhong; Xing Sun; Zhao-Wen Wang; Gui-Long Deng; Fu-Dong Yu; Ying-Ming Xue; Hua-Mei Tang; Zhi-Hai Peng; Xiao-Liang Wang
Journal:  Tumour Biol       Date:  2015-10-04

10.  Molecular targets and signaling pathways regulated by nuclear translocation of syndecan-1.

Authors:  Tünde Szatmári; Filip Mundt; Ashish Kumar-Singh; Lena Möbus; Rita Ötvös; Anders Hjerpe; Katalin Dobra
Journal:  BMC Cell Biol       Date:  2017-12-08       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.